Ravi Nalliah retains place in the distinguished Medicine Maker Power List.
Now in its 4th year, the annual Medicine Maker Power List awards celebrate the achievements of some of the most influential figures within the pharma industry. The awards recognize individuals across four categories: Masters of the Bench, Industry Influencers, Business Captains and Champions of Change, reflecting the great talent within the industry, from pioneering scientists to entrepreneurs and regulators.
This year’s List mirrors the ongoing evolution of the pharma industry, with the emergence of advanced therapies being reflected in a record number of places awarded to scientists and business people from the cell and gene space. The awards also feature a record number of nominees from Asia, including the first employee of a Chinese company – reflecting the increasing importance of China to the global industry.
After entering the Power List for the first time in 2018, Ravi Nalliah (TrakCel CEO) has successfully retained his position within the “Business Captains” category of the list in recognition of the growth and innovation demonstrated by TrakCel within the pharma industry.
Speaking of the award, Ravi Nalliah commented:
“I am honored to be featured on the ‘Medicine Maker Power List’ alongside some of the most pioneering scientists, regulators and thought leaders. Retaining my position in the 2019 Power List is testament to the commitment and innovation of my colleagues at TrakCel and our shared vision to support the delivery of life-changing advanced therapies”.
TrakCel is the market leading developer of clinical orchestration software designed to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel’s software has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel’s solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining compliance and traceability.
More information about the Medicine Maker awards can be found here.